Latest Conference Articles

September 28th 2014, 8:08am

ESMO Congress: Lung Cancer

Vintafolide in combination with docetaxel showed improvements in PFS and OS compared with single-agent docetaxel as second-line treatment of patients with folate receptor–positive NSCLC.

September 28th 2014, 7:29am

ESMO Congress

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the results from a phase I trial of nivolumab and ipilimumab for the treatment of patients with advanced melanoma.

September 27th 2014, 10:42am

ESMO Congress: Lung Cancer

Patients with advanced lung cancer had improved appetite, less weight loss, and a significant increase in lean body mass when treated with the ghrelin agonist anamorelin.

September 27th 2014, 7:46am

ESMO Congress: Head and Neck Cancer

Afatinib delayed disease progression for approximately one month longer than chemotherapy and helped prevent painful symptoms from worsening for patients with relapsed or metastatic head and neck squamous cell carcinoma.

September 27th 2014, 7:32am

ESMO Congress: GI Cancers

Dovitinib, an investigational oral tyrosine kinase inhibitor (TKI), demonstrated a "manageable" safety profile while controlling disease in about half of patients with advanced gastrointestinal stromal tumor (GIST) who had discontinued treatment with imatinib due to disease progression or intolerance

September 27th 2014, 7:18am

ESMO Congress: Lung Cancer

Peter Emtage, discusses a phase I open-label study evaluating the safety and tolerability of MEDI4736 in combination with tremelimumab for the treatment of patients with advanced non-small cell lung cancer.

September 27th 2014, 6:24am

ESMO Congress: GU Cancers

Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Professor and Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses results from the phase II STRIDE study.

September 25th 2014, 10:42am

ESMO Congress: Breast Cancer

Treatment with the combination of bevacizumab and chemotherapy improved PFS and OS in women with HER2-negative metastatic breast cancer.

September 16th 2014, 4:14pm

ASTRO Annual Meeting

High pretreatment levels of serum VEGF-A and TGF-β1 indicated significantly worse disease-free survival (DFS) following neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.

September 16th 2014, 2:30pm

ASTRO Annual Meeting

Timing of metastatic development, lymph node involvement, and type of disease all factor into the overall survival rate of patients with stage IV NSCLC.

September 16th 2014, 2:11pm

ASTRO Annual Meeting

The combination of chemotherapy and stereotactic ablative radiotherapy (SABR) may allow patients with locally advanced pancreatic cancer to undergo surgery, a procedure that might not have otherwise been an option

September 16th 2014, 2:08pm

ASTRO Annual Meeting

With the use of MRI imaging to restrict doses to erectile tissues, nearly half of men treated with external beam radiation therapy (EBRT) for prostate cancer were able to be sexually active without aids or medications 5 years later, and nearly 80% could be sexually active if such support was an option

September 16th 2014, 2:03pm

ASTRO Annual Meeting

When given along with radiation therapy to men with high-risk prostate cancer, 18 months of androgen-deprivation therapy (ADT)-as opposed to a 36-month course-not only generates similar long-term outcomes, but results in a better quality of life

September 15th 2014, 1:00pm

ASTRO Annual Meeting

Radiotherapy is equally as effective in the palliation of dysphagia (difficulty swallowing) as chemoradiotherapy for patients with advanced esophageal cancer

September 15th 2014, 9:39am

ASTRO Annual Meeting

Despite a recent decline in utilization, consolidated radiation therapy has been shown to improve 10-year survival rates for patients with stage I/II Hodgkin's lymphoma following treatment with chemotherapy

September 11th 2014, 8:34am

Breast Cancer Symposium

The combination of letrozole with either the CDK4/6 inhibitor LEE011 or the PI3 kinase Inhibitor BYL719 demonstrated clinical activity for women with ER-positive, HER2-negative breast cancer.

September 9th 2014, 7:15am

Breast Cancer Symposium

Julie R. Gralow, MD, discusses the use of bisphosphonates in early-stage breast cancer.

September 8th 2014, 10:59am

Breast Cancer Symposium

Elisa K. Chan, MD, discusses improving mammography screening rates with signed letters from physicians. Chan worked for the BC Cancer Agency during the study.

September 7th 2014, 5:01am

Breast Cancer Symposium

The addition of trastuzumab to fulvestrant prolonged responses compared with fulvestrant alone for certain patients with metastatic breast cancer.

September 6th 2014, 12:16pm

Breast Cancer Symposium

A novel HER2-derived peptide vaccine designed to stimulate CD8+ cytotoxic T-lymphocytes reduced the rate of breast cancer recurrence and proved safe and well tolerated in the adjuvant setting.